Healthy Skepticism Library item: 8693
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Hollmer M.
Biotech takes aim at large anti-estrogen markets.
Nat Biotechnol 2006 Dec; 24:(12):1455-6
http://www.nature.com/nbt/journal/v24/n12/full/nbt1206-1455.html
Abstract:
Next year, San Diego-based Ligand Pharmaceuticals is hoping to launch a third-generation selective estrogen receptor modulator (SERM) that it developed with Wyeth of Collegeville, Pennsylvania.
Keywords:
Publication Types:
News
MeSH Terms:
Biotechnology/economics*
Clinical Trials
Drug Industry/economics*
Hormone Replacement Therapy/adverse effects
Humans
Selective Estrogen Receptor Modulators/adverse effects
Selective Estrogen Receptor Modulators/chemical synthesis
Selective Estrogen Receptor Modulators/economics*
Substances:
Selective Estrogen Receptor Modulators
Notes:
Free full text
